Title: Antibody Mediated Rejection in Cardiac Allografts is Associated with Favorable Survival in Adherent Patients

Authors: Paul J. Kim,[1] Vincenzo Cusi,[1] Ashley Cardenas,[2] Yuko Tada,[1] Florin Vaida,[3] Nicholas Wettersten,[4] Jennifer Chak,[1] Priyesha Bijlani,[1] Victor Pretorius,[5] Marcus Anthony Urey,[1] Gerald P. Morris,[2] Grace Lin[2]

Affiliations: 1. UC San Diego Health, San Diego, CA. 2. Department of Pathology, University of California, San Diego, California, USA 3. Department of Family Medicine and Public Health, UC San Diego, La Jolla, CA. 4. Cardiology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA. 5. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of California, San Diego, California, USA

Address for Correspondence:

Paul J. Kim, MD
Division of Cardiovascular Medicine
Department of Medicine
UC San Diego Health

9452 Medical Center Drive, MC 7411
La Jolla, CA 92037
Tel: 858-246-0638
Fax: 858-534-2000

Abbreviations

ACR, Acute cellular rejection
AMR, Antibody mediated rejection
BMI, Body mass index
CAV, Cardiac allograft vasculopathy
CMV, Cytomegalovirus
DCD, Donation after cardiac death
DSA, Donor-specific antibodies
ECMO, Extracorporeal membrane oxygenation
EMB, Endomyocardial biopsies
HTx, Heart transplantation
ISHLT, International Society for Heart and Lung Transplantation
LVEF, Left ventricular ejection fraction
MCS, mechanical circulatory support
pAMR, pathological antibody mediated rejection
PCWP, pulmonary capillary wedge pressure
PRA, Panel of reactive antibodies
PHM, Predicted heart mass
pMCS, percutaneous mechanical circulatory support
UC San Diego Health, University of California, San Diego Health
UNOS, United Network for Organ Sharing

Abstract:

Background:

Serial C4d immunostaining of surveillance endomyocardial biopsies (EMB) and testing for donor specific antibodies (DSA) are routinely performed in the first year of heart transplantation (HTx) in adult patients. C4d and DSA positivity have not been evaluated together with respect to clinical outcomes in the contemporary era (2010-current).

Methods:

This was a single center, retrospective study of consecutive EMBs performed between November 2010 and April 2023. The primary objective was to determine whether C4d and/or DSA positivity could predict death, cardiac death, or retransplant. Secondary analyses included cardiac allograft dysfunction (< 50%; left ventricular ejection fraction) and cardiac allograft vasculopathy (CAV; $\geq$ ISHLT grade 2). Cox proportional hazards models were used for single predictor analysis and multipredictor models.

Results:

A total of 6,033 EMBs from 519 HTx patients were reviewed for the study. There was no significant difference (p_{adj} = 0.110) in all-cause mortality or cardiac retransplant between the four groups: C4d+/DSA+, C4d+/DSA-, C4d-/DSA+, and C4d-/DSA-. However, the risk for cardiac mortality or retransplant was significantly increased in C4d+/DSA+ compared to C4d-/DSA- patients (HR = 4.73; p_c = 0.042) but not significantly different in C4d+/DSA- compared to C4d-/DSA- patients (p_c = 1.000). Similarly, the risk for cardiac allograft dysfunction was significantly increased in

C4d+/DSA+ compared to C4d-/DSA- patients (HR 3.26; p_c = 0.001) but not significantly different in C4d+/DSA- compared C4d-/DSA- patients (p_c = 1.000). After adjusting for medical nonadherence, C4d/DSA status continued to predict cardiac allograft dysfunction but no longer predicted cardiac death or retransplant.

Conclusions:

Adherent C4d+/DSA+ HTx patients show significantly increased risk for cardiac allograft dysfunction but not cardiac mortality or retransplant. In contrast, C4d+/DSA- patients represent a new immunopathologic group with a clinical course similar to normal HTx patients.

Introduction

The pathologic criteria for antibody mediated rejection (AMR) in heart transplant (HTx) patients has made significant progress since its early description in literature,[1–3] and evolved to the current application of immunopathologic criteria that includes C4d, C3d, and/or CD68 immunostaining, defined by the International Society for Heart and Lung Transplantation (ISHLT) Working Formulation in 2013.[4,5] Subsequently, C4d immunostaining has become the most commonly described method for pathological antibody mediated rejection (pAMR) grading.[6–12]

The immunopathologic criteria from the ISHLT created five different pAMR grades, including two subtypes of pAMR1 - pAMR1(I$^+$) and pAMR1(H$^+$). However, the clinical significance of the different immunopathologic grades are not fully understood.[5,13,14] Furthermore, the clinical significance of C4d positivity itself remains an area of active research, especially since the 2013 ISHLT Working Formulation and 2015 AHA Scientific Statement.[4,5,7,9,10,12,14]

The association of DSA positivity and poor clinical outcomes have also been well documented.[8,15–17] However, prior studies describe mixed results with respect to risk to DSA class type as well as conflicting risk for clinical outcomes.[18–20] Thus, this study aimed to examine the role of both C4d and DSA positivity in adult HTx patients related to clinical outcomes, including all-cause death, cardiac death or retransplant.

Materials and Methods:

Data Sharing

The data that support the findings of this study are available upon request.

Study Design

Consecutive heart transplant (HTx) patients who were 18 years of age or older and underwent right ventricular endomyocardial biopsy (EMB) between November 2010 to April 2023 were retrospectively reviewed. At the University of California, San Diego Health (UC San Diego Health), the typical EMB surveillance protocol includes EMBs performed biweekly for the first 3 months and monthly afterwards during the first year post-HTx. After 1 year post-HTx, EMBs were typically performed as for cause EMBs. UC San Diego protocol includes C4d immunofluorescence at 2 and 4 weeks, and at 3, 6 and 12 months during surveillance EMBs in addition to for cause EMB indication as per the International Society for Heart and Lung Transplantation (ISHLT).[4,5] DSA testing is also performed at the same time intervals for surveillance indication and whenever there is clinical concern for AMR. The authors (VC, AC, PB, JC) collected patient data and clinical outcomes from the electronic medical record. Approval for this study was provided by the UC San Diego Health Office of IRB Administration (IRB #805675). This study adheres to the principles of the Declaration of Helsinki formulated by the World Medical Association and the US Federal Policy for the Protection of Human Subjects.

Comparison Groups

HTx patients with C4d and DSA testing information were included for this study. Additionally, since the specific goal of this study was to evaluate clinical outcomes associated with C4d and DSA positivity, patients diagnosed with pathological antibody mediated rejection (pAMR) without positive C4d immunofluorescence (i.e., by histology or CD68 positivity)[4] were also excluded from the study. C3d immunofluorescence was not used at UC San Diego during the study period.

Pathological Tissue Exams and DSA testing

The results of pathological tissue exams were collected for each EMB. C4d immunofluorescence was performed starting November 2010 at UC San Diego Health. C4d positivity was defined as multifocal/diffuse weak or strong staining as per the ISHLT.[4] Acute cellular rejection (ACR) grading was performed per ISHLT guidelines[21] and grades 2R and 3R were defined as clinically significant ACR. pAMR grading scheme for AMR[4] was performed and grades $\geq$ pAMR 1 were considered positive for this study. Donor specific antibody (DSA) testing was performed using FlexMap 3D (Luminex, Austin, Tx) instruments with normalized mean fluorescence intensity values of 3,000 used to identify "positive" antibodies.[22] For this study, concurrent DSA positivity was defined by a positive DSA result within a month of the C4d result.

Clinical Outcomes and Variables

All patients were followed for all-cause death. Cause of death was adjudicated by two experienced HTx cardiologists (NW and PJK). When there was a disagreement, a third cardiologist (YT) made the final determination. Other clinical outcomes included: ISHLT cardiac allograft vasculopathy (CAV) grade 2 or greater[23], cardiac retransplant, cardiac allograft dysfunction (echocardiogram demonstrating left ventricular ejection fraction < 50% and excluding primary graft dysfunction[24]), and future episodes of AMR and/or ACR. For this study, if cardiac allograft dysfunction and/or

CAV were noted within 6 months of a C4d result and no other recent studies identified, then cardiac allograft dysfunction and/or CAV would be recorded as concurrent with the C4d result. Additional clinical variables recorded included: recipient age, sex, race/ethnicity, recipient body mass index (BMI), recipient multiorgan status, recipient blood type, United Network for Organ Sharing calculated panel of reactive antibodies, durable mechanical circulatory support (MCS) at the time of HTx, etiology of cardiomyopathy pre-HTx, donor age, donor sex, donor BMI, donation after cardiac death donor status, predicted heart mass (PHM) difference, extracorporeal membrane oxygenation (ECMO) pre- and post-transplant, percutaneous mechanical circulatory support (pMCS) pre- and post-transplant, cold ischemic time, use of induction therapy, cytomegalovirus status, de novo DSA status, DSA class I and II serologic subtypes, first pAMR grade at time of C4d positivity, highest pAMR grade, total number of separate AMR episodes, immunomodulatory treatment for c4d positivity, history of ACR, ACR grade at time of C4d positivity, indication of EMB at the time of C4d positivity, and intracardiac pressure measurements and cardiac index by Fick calculation at the time of C4d positivity. Immunomodulatory treatment for AMR refers to a significant change in a subject's immunomodulatory regimen including: initiation or increase in corticosteroids to a prednisone equivalent of 40 mg/day or higher, intravenous immune globulin, plasmapheresis, rituximab, thymoglobulin, and/or bortezomib use.

Medical Nonadherence

Documentation by any clinical team member of medical nonadherence after HTx was recorded as nonadherence by the authors (VC, AC, PB, JC). Medical adherence was considered broadly post-HTx, based on the clinical team's assessment and charting, and not exclusive to adherence to immunosuppressive medications.

Statistical Analysis

Continuous variables were expressed as mean + standard deviation (SD) for normally distributed variables or median and interquartile range (IQR) for non-normally distributed variables and compared with the use of the Student's t-test or Wilcoxon rank-sum test, respectively. The Kruskal-Wallis test was used for multiple group comparisons of continuous data. Categorical variables were expressed as counts and percentages and compared between groups using either the Pearson's chi-square or Fisher's exact test whenever any observed counts were $\leq$ 5. If the null hypothesis was rejected, pairwise group comparisons using the Bonferroni-Holm procedure were subsequently performed. The agreement rate between the two adjudicators for clinical outcomes was performed using Cohen's kappa statistics.

The association of C4d/DSA groups with time to event outcomes (all cause death, cardiac death or retransplant, cardiac allograft dysfunction, CAV, C4d positivity, DSA positivity, C4d+/DSA+ positivity, and future treated ACR) was evaluated using single predictor and multipredictor Cox proportional hazards models. The multipredictor model adjusted for potential confounders (recipient, donor, and appropriate transplant characteristics) via backward model selection with p-value $\leq$ 0.15 threshold for inclusion. Additional exploratory analyses investigated factors associated with time to event outcomes using Cox models applying a similar backwards model selection procedure, except for time to CAV analysis where a forwards model selection procedure was used due to a relatively low number of events compared to the number of predictors evaluated. Medical nonadherence was only evaluated as a potential predictor in exploratory analyses. Cause-specific hazard models were used to address etiologic questions. The Fine-Gray subdistribution hazard models were also performed to evaluate the effect of covariates on competing risks.

Analysis was conducted in R (R Core Team, 2022) with survival (v3.5-5)[25] for Cox proportional hazards regression, cmprsk (v2.2-11) for Fine-Gray subdistribution hazard models[26], and fmsb (v0.7.5) for Cohen's kappa.[27] Figures were produced using the package ggplot2.[28] The corrected p-values are designated as p_c. For single hypothesis testing we report the unadjusted p-value unless stated otherwise. P or $p_c < 0.05$ are considered significant.

Results

Patient Demographics

A total of 560 HTx patients were identified and deemed potentially eligible for the study (**Figure 1**). Of these, 31 patients were excluded for not having documentation of C4d immunofluorescence. Because our study was specific to C4d and DSA positivity, 10 patients were also excluded for the diagnosis of pAMR using CD68[+] immunostaining or histology criteria[4] without C4d positivity.

Baseline characteristics of the study population are depicted in **Table 1.** Patients were typically male (81%) and non-hispanic white (41%) with a mean age of 54 ± 14 years at the time of HTx. There were 1,855.1 person-years in this study from HTx to end of follow-up.

The primary reason for transplantation was non-ischemic cardiomyopathy (60%). Highly sensitized (panel of reactive antibodies >= 10%)[29] patients comprised 19% of the study cohort. Induction therapy was used in 246 patients (47%) and 73 patients (13%) underwent multi-organ transplants. There were 89 patients (16%) that had a documented history of medical nonadherence post-HTx.

C4d and DSA positivity

A total of 6,033 EMBs from 519 patients, including 4 cardiac retransplants, were included for this study. Patients were divided into 4 groups based on history of C4d and DSA positivity. There were 40 C4d+/DSA+, 25 C4d+/DSA-, 94 C4d-/DSA+, and 360 C4d-/DSA- patients. There were 65 (12.5%) patients that had C4d positivity on immunofluorescence and 134 (25.8%) patients with DSA positivity (**Figure 2**; **Supplementary Figure S1**). Of the positive DSAs, 122 (94.6%) were

de novo, 55 (41.0%) were class 1 DSAs, 109 (81.3%) were class 2 DSAs, and 31 (23.1%) were both class 1 and 2 DSAs. Most C4d+ EMBs (92.3%) occurred in the setting of ACR grades 0R or 1R. CAV was known or diagnosed at the time of C4d positivity in 5 of the 20 patients that had been evaluated for CAV to date. Cardiac allograft dysfunction was known or diagnosed at the time of C4d positivity in 16 (24.6%) patients.

Association of C4d and DSA status with all cause death, cardiac death, or retransplant

Of the 519 patients, 58 (11.2%) died or underwent cardiac retransplant during the follow-up period (**Supplementary Table S1**). Of the deaths, 5 (9.3%) were due to cancer, 16 (29.6%) were due to cardiac causes, 22 (40.7%) were due to infection, 7 (13.0%) were due to other causes, and 4 (7.4%) were due to unknown causes. Initial adjudication of cause of death was in agreement 88.1% of the time with a Cohen's kappa of 0.84 (0.72, 0.96; p < 0.001).

There was no significant difference in all-cause mortality or cardiac retransplant between the four groups (**Figure 3**; adjusted p-value = 0.110). However, there was a significantly increased risk in cardiac mortality or retransplant in C4d+/DSA+ compared to C4d-/DSA- patients (**Figure 4**; hazard ratio [HR] = 4.73; 95% confidence interval [CI] 1.57-14.27; p_c = 0.042). There was no significant difference in cardiac mortality or transplant in C4d+/DSA- compared to C4d-/DSA- patients (p_c = 1.000). The Fine-Gray subdistribution hazard model also demonstrated consistent findings with the cause-specific hazard model (p = 0.001). Of note, we observed all cardiac deaths of patients with C4d positivity occurred in-hospital.

Predictors for clinical outcomes

For all-cause mortality or cardiac retransplant, we found ECMO post-HTx, sex mismatch, recipient race/ethnicity, medical nonadherence, recipient BMI, and PHM difference to be significant independent risk factors (**Supplementary Table S2**). For cardiac mortality or retransplant, only medical nonadherence (HR 3.45; 95% CI, 1.27-9.36; p = 0.015; **Table 2 and Supplementary Table S3**) and recipient age (HR 0.97 per year increase; 95% CI, 0.94-0.99; p = 0.019) were found to be significant from our multipredictor model.

For prediction of DSA positivity, we found recipient age, medical nonadherence, and allosensitization status pre-HTx by panel of reactive antibodies (PRA) to be significant independent risk factors (**Supplementary Table S4**). For prediction of C4d positivity, we found class 1 and 2 antibodies, medical nonadherence, and female recipient sex to be significant independent predictors (**Supplementary Table S5**).

For cardiac allograft dysfunction, we found medical nonadherence, C4d/DSA status, PHM difference, HTx indication, and ECMO pre- and post-HTx to be significant independent predictors (**Table 3 and Supplementary Table S6**). Post hoc analysis of C4d/DSA status demonstrated significantly increased risk for cardiac allograft dysfunction in C4d+/DSA+ compared to C4d-/DSA- patients (HR 3.26; 95% CI, 1.75-6.08; p_c = 0.001). There was no significant difference in risk for cardiac allograft dysfunction in C4d+/DSA- (p_c = 1.000) and C4d-/DSA+ (p_c = 1.000) compared to C4d-/DSA- patients. We did not find severity of the ACR grade with concurrent C4d positivity to correlate with cardiac allograft dysfunction (p = 0.227). We also did not find the severity of the pAMR grade with concurrent C4d positivity (p = 0.313) nor the number of AMR episodes (p = 0.742) to correlate with cardiac allograft dysfunction.

For future CAV, given the relatively low number of events (n = 30), we performed a post hoc pairwise comparisons of the primary variable of interest, C4d/DSA patient groups, and adjusted

for identified confounders (**Supplementary Table S7**). We observed a trend for predicting CAV in C4d+/DSA+ compared to C4d-/DSA- patients (HR 3.52; 95% CI, 1.21-10.24; p_c = 0.063). The C4d+/DSA- group (p_c = 0.527) did not show a significant difference compared to C4d-/DSA- patients for predicting CAV. Of note, 360 (69.4%) patients from the study cohort, 54 (83.1%) of all C4d+ patients, 19 (82.6%) of C4d+ patients with cardiac allograft dysfunction, and 12 (85.7%) of the nonadherent C4d+ patients with cardiac allograft dysfunction were evaluated for CAV by coronary angiography. Of the 7 nonadherent C4d+/DSA+ patients with cardiac mortality or retransplant, there was only 1 patient where a coronary angiogram result was not performed within 6 months prior to the cardiac death.

Comparison of C4d+/DSA+ and C4d+/DSA- groups

We found no significant difference in cardiac index by right heart catheterization in C4d+/DSA+ (2.6 ± 0.8 LPM/m^2) compared to C4d+/DSA- patients (2.8 ± 0.6 LPM/m^2; p = 0.182) at the time of C4d positivity. However, median pulmonary capillary wedge pressure (PCWP) was significantly increased in C4d+/DSA+ (17 mmHg; IQR, 12-22 mmHg) compared to C4d+/DSA- patients (13 mmHg; IQR, 8-16 mmHg; p = 0.015).

Treatment for AMR varied widely and was significantly more likely in C4d+/DSA+ compared to C4d+/DSA- patients (80.0% vs 24.0%; OR 12.03; 95% CI, 3.34-50.73; p < 0.001). Intravenous immunoglobulins (62.5% vs 16.7%, p = 0.071) and plasmapheresis (59.4% vs 16.7%, p = 0.082) were given more often to treated C4d+/DSA+ compared to C4d+/DSA- patients. In contrast, we found no significant difference in use of intravenous methylprednisolone (43.8% vs 50%, p = 1.0), oral prednisone 40 mg/day or higher (21.9% vs 33.3%, p = 0.613), antithymocyte globulins (15.6% vs 0, p = 0.570), rituximab (12.5% vs 16.7%, p = 1.0) in treated C4d+/DSA+ compared to C4d+/DSA- patients. We found no significant difference in terms of types of treatment prescribed

comparing medical compliance versus noncompliance subgroups within the C4d+/DSA+ group (data not shown).

Separate episodes of future treated AMR recurred in 25% of C4d+/DSA+ patients. C4d+/DSA+ patients showed a trend towards increased proportion of future treated ACR episodes compared to C4d-/DSA- patients (OR 2.54; 95% CI, 0.98-6.04; p_c = 0.066), while C4d+/DSA- patients did not show a significant difference compared to C4d-/DSA- patients (p_c = 0.512). There was no significant difference in proportion of mixed rejection between the C4d+/DSA+ and C4d+/DSA- groups (7.5% vs 8.0%; p = 1.000).

The C4d+/DSA+ group showed a significantly increased median time to C4d positivity compared to the C4d+/DSA- group (**Supplementary Figure S1**; 33.6 vs 3.6 weeks; p = 0.004). For the C4d+/DSA+ group, 36 (90.0%) patients demonstrated positive DSA concurrent with C4d positivity and the median time from DSA to C4d positivity was 4.5 days (IQR, 0.0-41.0 days) for these patients. Of the 4 patients that did not demonstrate positive DSA concurrent with C4d positivity, 3 patients demonstrated positive DSA within 1 year of C4d positivity while 1 patient demonstrated positive DSA after 1 year. Despite an initially negative DSA, three of the four C4d+/DSA+ patients were still treated for AMR.

With regards to median time to DSA positivity, the C4d+/DSA+ group showed no significant difference compared to the C4d-/DSA+ group (24.6 vs 18.3 weeks; p = 0.975). However, the C4d+/DSA+ group showed significantly increased concurrent class 1 and 2 DSAs compared to the C4d-/DSA+ group (OR 7.40; 95% CI, 2.86-20.18; p < 0.001).

Medical nonadherence by C4d/DSA status

We observed a significant difference in medical nonadherence by C4d/DSA status (**Figure 5**; p < 0.001). In pairwise comparisons, medical nonadherence was significantly increased in C4d+/DSA+ compared to C4d-/DSA- patients (OR 7.13; 95% CI, 3.35-15.22; p_c < 0.001). In comparison, C4d+/DSA- patients did not show a significant difference compared to C4d-/DSA- patients (OR 1.79; 95% CI, 0.50-5.26; p_c = 0.518). We also found nonadherent patients were significantly less likely to be at their target immunosuppressive drug trough levels at the time of C4d positivity (61% vs 92%; OR 0.13; 95% CI, 0.02-0.64; p = 0.006).

Discussion

In this retrospective cohort of 544 HTx patients with greater than 2,000 patient-years of follow-up, the following key findings were observed. First, C4d+/DSA+ patients demonstrated significantly increased cardiac morbidity, mortality, or retransplant when compared to C4d+/DSA- patients. Second, C4d+/DSA+ patients demonstrated significantly increased medical nonadherence compared to C4d+/DSA- patients. Third, after accounting for nonadherence, C4d+/DSA+ status still predicted increased cardiac allograft dysfunction but no longer predicted increased cardiac mortality or retransplant.

AMR is typically diagnosed by pathologic criteria, set forth in the last Working Formulation by the ISHLT, which has greatly improved the sensitivity for the diagnosis of pAMR.[4,30] However, we show that the new immunopathologic criteria and the recommendation to routinely perform DSA testing[31] in the first year after HTx contributed to the classification of a novel C4d+/DSA- group that has not been well described in the contemporary era (2010 to current).[8,12,20] In the current study, we find that C4d+/DSA- patients are a clinically distinct group compared to C4d+/DSA+ patients. C4d+/DSA+ patients demonstrated significantly increased cardiac allograft dysfunction

and cardiac death or retransplant compared to C4d+/DSA- patients. After adjusting for medical nonadherence, C4d+/DSA+ patients continued to demonstrate a significantly increased risk in cardiac allograft dysfunction and a trend towards increased CAV prevalence. Thus, we show that C4d+/DSA+ patients are at higher risk for future clinical events compared to C4d+/DSA- patients. Recently, RNA-sequencing of EMBs demonstrated marked transcriptomic differences between DSA+ and DSA- groups in AMR patients, with significant upregulation of genes related to immunity in DSA+ AMR patients.[14] Our study also supports the finding that C4d+/DSA- patients represent a new immunopathologic group, with a clinical course not significantly different compared to the C4d-/DSA- group.

The onset of C4d positivity occurred significantly earlier in the C4d+/DSA- group, at 1 month post-HTx, compared to 9 months post-HTx in the C4d+/DSA+ group. Although initial AMR literature described early onset of positive cardiac immunostaining,[32–34] more recent literature often describe a bimodal distribution of "early" and "late" C4d immunostaining.[7,8,11,35–40] A potential reason for early positive C4d immunostaining has been previously attributed to complement activation related to reperfusion injury at the time of HTx.[41–43] Our study findings support the hypothesis that the mechanism for complement activation and deposition in C4d+/DSA- patients is different from C4d+/DSA+ patients and possibly the result of reperfusion injury.

We also found the clinical differences at time of presentation to be significantly different for the C4d+/DSA+ compared to C4d+/DSA- patients. The majority (98%) of C4d+/DSA+ patients demonstrated DSA positivity either concurrent with or within a year of C4d positivity. Additionally, C4d+/DSA+ patients presented with significantly increased intracardiac filling pressures[7,44] at the time of C4d positivity compared to C4d+/DSA- patients. Consequently, the management of C4d+/DSA+ patients did not appear to be affected necessarily by the DSA result at the time of C4d positivity. The majority (80%) of C4d+/DSA+ patients received some type of

immunomodulatory treatment in addition to their baseline immunosuppression regimen. However, the treatment regimens varied widely with intravenous immunoglobulins and plasmapheresis being more frequently used compared to others.[5,7]

A novel finding from our study is that medical nonadherence is significantly correlated to C4d+/DSA+ status and ultimately, cardiac death or retransplant. We found medical nonadherence to be significantly associated with DSA positivity, C4d positivity, cardiac allograft dysfunction, and cardiac death or retransplant. However, we did not find medical nonadherence to be significantly associated with CAV. We believe this finding does not contradict prior literature describing correlation observed between AMR and CAV.[7,9,20,37,44–49] Instead, our study results complement current literature and show that there is more than one mode of cardiac death in the C4d+/DSA+ group and is associated with adherence status. Thus, we hypothesize that medical nonadherence contributes to DSA production, C4d deposition, subsequent cardiac allograft dysfunction, and resultant cardiac death or retransplant. As a related observation, we find in our study that while adherent C4d+/DSA+ patients are at an increased risk for cardiac allograft dysfunction, they do not demonstrate the increased risk for cardiac death or retransplant as do nonadherent C4d+/DSA+ patients. However, the mechanism(s) for why nonadherent C4d+/DSA+ patients are at an increased risk of cardiac death or retransplant is unclear. We did not find a correlation with cardiac allograft dysfunction and severity of pAMR grading, number of AMR episodes, nor mixed acute rejection. Further study of cardiac allograft dysfunction and prediction for cardiac death or retransplant will be important to better understand this relationship.

In our study cohort, class 2 DSA positivity was a relatively common occurrence (21%),[8,11,19,20,50–52] while HTx patients with both class 1 and 2 DSA positivity was much less frequent (6%).[53] Furthermore, we found that patients who were both class 1 and 2 DSA positive were at a significantly increased risk for being in the C4d+/DSA+ rather than C4d-/DSA+ group. This

observation contributes to existing literature[8,17,20,54,55] and is important for HTx patients that become DSA positive as we did not find the majority of these patients (i.e., C4d-/DSA+ group) to be at increased risk for all cause death, cardiac death or retransplant, CAV, and cardiac allograft dysfunction compared to C4d-/DSA- patients. Further study of class 1 and 2 DSAs, including at a higher molecular resolution[22,56], may provide additional insights of the risks specific DSAs pose to HTx patients.

Due to significant variation in treatment and as most (80%) C4d+/DSA+ patients received some form of immunomodulatory treatment, we could not make any confident conclusions on the effect of treatment on clinical outcomes within the C4d+/DSA+ group. Randomized control trials to better identify C4d+/DSA+ patients that need treatment and what type of immunomodulatory treatment will be important going forward.[7,57,58]

Finally, our study adds to the evolving literature of "biopsy-negative rejection" after HTx.[59] We show cardiac allograft dysfunction occurs most frequently in the C4d+/DSA+ group but also occurs in other C4d/DSA groups without an identified cause. With continued research in non-HLA antibodies[60] and immunopathology,[13,14,61] particularly with RNA-sequencing, we believe we will see further classification of immunophenotypes and greater understanding biologically and clinically of these patients.

Limitations

This study should be interpreted within the context of several important limitations. First, this was a retrospective study from a single center and may not necessarily represent the experience of other centers with different patient demographics and variations in post-HTx management. Second, the number of cardiac deaths or retransplants were low for all groups. However, we still

found the time to cardiac death or retransplant to be significantly different in C4d+/DSA+ compared to C4d-/DSA- patients but this was no longer significant after adjusting for medical nonadherence. Third, while our study represents a sizable cohort relative to other single center studies,[7–9,18,62] the C4d+/DSA- group represented a minority of total HTx patients. Thus, our study remains underpowered to detect smaller differences and larger, multicenter studies should be performed to confirm our findings. Fourth, we chose C4d immunofluorescence as a prognostic biomarker[12] instead of pAMR grading because its simplicity and potential concerns of "overcalls" of pAMR2 without C4d positivity.[63] However, we recognize there is ongoing research of pAMR1(H$^+$) and more study in this area is needed.[13,14]

Conclusions

C4d immunofluorescence and DSA positivity are simple yet useful biomarkers in the contemporary era for HTx patients with AMR. Medically adherent C4d+/DSA+ patients show increased cardiac allograft dysfunction but not increased cardiac death or retransplant compared to normal HTx patients. C4d+/DSA- patients represent a new immunopathologic group with a clinical course similar to that of normal HTx patients.

Acknowledgements: The authors acknowledge Taylor Tran, BS, from UC San Diego Health for his contribution to data collection, Hyoungmin Kim, from UC San Diego Health for his contribution to data collection, and Layla Myers, BS, from UC San Diego Health for her contribution to data collection.

Author contributions:

PJK: conceptualization, writing, review and editing, data curation, adjudication of clinical outcomes, project administration; VC: writing, review and editing, data curation, project administration; AC: conceptualization, writing, data curation; YT: writing, review and editing, data curation, adjudication of clinical outcomes; FV: writing, reviewing, editing, and statistical analyses; NW: writing, review and editing, data curation, adjudication of clinical outcomes; JC: writing, review and editing, data curation; PB: writing, review and editing, data curation; VP: writing, review and editing; MAU: writing, review and editing; GPM: writing, review, and editing, project administration; GL: conceptualization, writing, review and editing, project administration.

Figure 1. Flow diagram. HTx, heart transplantation; DSA, donor-specific antibodies.

Figure 2. Representative photomicrographs of a C4d+/DSA+ patient. A. Strong, diffuse endothelial staining (white arrowhead) of capillaries by C4d immunofluorescence (40x). B. Cardiac allograft vasculopathy with concentric intimal fibrosis (black arrow) and endothelial swelling (black arrowhead). C and D. Hematoxylin and eosin staining at 10x (C) and 40x (D) demonstrating intravascular distribution of macrophages (white arrow) with associated myocyte damage. DSA, donor-specific antibodies.

Figure 3. Kaplan-Meier Curves for Overall Survival by C4d/DSA status. There was no significant difference in overall survival between groups by C4d/DSA status (adjusted p-value = 0.143). DSA, donor-specific antibodies.

Number at risk							
C4d+/DSA+	40	39	37	36	34	31	29
C4d+/DSA-	25	23	22	20	19	19	17
C4d-/DSA+	94	92	86	77	72	61	56
C4d-/DSA-	359	332	286	245	220	188	173

Figure 4. Kaplan-Meier Curves for Freedom From Cardiac Death or Retransplant. There was a significantly increased cardiac mortality or retransplant in C4d+/DSA+ compared to C4d-/DSA- patients (p_c = 0.042). However, there was no significant difference in cardiac mortality or retransplant in C4d+/DSA- compared to C4d-/DSA- patients (p_c = 1.000). DSA, donor-specific antibodies.

Number at risk

	0	6	12	18	24	30	36
C4d+/DSA+	40	39	39	38	37	34	32
C4d+/DSA-	25	23	22	21	20	20	18
C4d-/DSA+	94	92	87	79	74	63	58
C4d-/DSA-	360	342	300	263	238	204	185

Figure 5. Proportion of Medical Nonadherence by C4d/DSA Status. C4d+/DSA+ group showed a significantly increased proportion of patients with medical nonadherence compared to C4d-/DSA- patients. However, C4d+/DSA- patients did not show a significant difference compared to C4d-/DSA- patients. DSA, donor-specific antibodies.

Table 1. Subject clinical characteristics. BMI, body mass index; CMV, cytomegalovirus; DCD, donation after cardiac death; ICM, ischemic cardiomyopathy; MCS, mechanical circulatory support; NICM, nonischemic cardiomyopathy; PHM, predicted heart mass; PRA, panel reactive antibodies; SD, standard deviation

Table 1					
	C4d+/DSA+ Group 1 (n = 40)	C4d+/DSA- Group 2 (n = 25)	C4d-/DSA+ Group 3 (n = 94)	C4d-/DSA- Group 4 (n = 360)	p-value
Donor characteristics					
Age, y, mean (SD)	30.97 (9.73)	37.33 (12.23)	31.47 (10.34)	33.08 (10.73)	0.127
Male, N (%)	26 (70.3)	19 (79.2)	74 (79.6)	298 (84.7)	0.118
Recipient characteristics					
Age, y, mean (SD)	44.85 (18.70)	59.56 (10.21)	51.19 (15.27)	55.67 (12.86)	<0.001
Male, N (%)	26 (65.0)	20 (80.0)	79 (84.0)	296 (82.2)	0.070
Race					0.232
Asian, N (%)	0	3 (12.0)	6 (6.4)	24 (6.7)	-
Black, N (%)	8 (20.0)	4 (16.0)	14 (14.9)	41 (11.4)	-
Native American, N (%)	0	0	2 (2.1)	2 (0.6)	-
Other Race, N (%)	5 (12.5)	1 (4.0)	11 (11.7)	38 (10.6)	-
Pacific Islander, N (%)	0	1 (4.0)	3 (3.2)	8 (2.2)	-
White, N (%)	27 (67.5)	16 (64.0)	58 (61.7)	247 (68.6)	-
Ethnicity					
Hispanic or Latino, N (%)	14 (35.0)	4 (16.0)	33 (35.1)	105 (29.2)	0.428
Recipient BMI, mean (SD)	26.66 (5.23)	28.47 (5.20)	27.63 (4.82)	26.92 (4.71)	0.280
Indication for Transplant					0.134
NICM, N (%)	25 (62.5)	17 (68.0)	56 (59.5)	210 (58.3)	-
ICM, N (%)	9 (22.5)	4 (16.0)	23 (24.5)	119 (33.1)	-
Mixed ICM/NICM (%)	1 (2.5)	3 (12.0)	6 (6.4)	15 (4.1)	-
Congenital, N (%)	4 (10.0)	0	6 (6.4)	11 (3.1)	-
Cardiac allograft failure, N (%)	1 (2.5)	1 (4.0)	3 (3.2)	5 (1.4)	-
Sensitized patients (PRA $\geq$ 10%), N (%)	10 (32.3)	2 (9.5)	21 (23.9)	51 (16.5)	0.067

Durable MCS, N (%)	11 (27.5)	9 (36.0)	33 (35.1)	131 (36.5)	0.751
Transplant characteristics					
Multiorgan transplant, N (%)	6 (15.0)	2 (8.0)	17 (18.1)	49 (13.6)	0.585
Cold ischemic time, min, mean (SD)	198.40 (50.75)	207.70 (60.10)	200.80 (58.66)	199.80 (65.52)	0.693
Sex mismatch (female D-male R), N (%)	3 (8.1)	1 (4.2)	10 (10.8)	28 (8.0)	0.787
PHM difference, mean (SD)	6.52 (23.20)	1.40 (20.56)	1.15 (16.80)	5.20 (20.80)	0.400
Induction therapy, N (%)	20 (57.1)	15 (62.5)	45 (48.4)	166 (45.7)	0.358
DCD, N (%)	3 (7.5)	4 (16.0)	12 (12.8)	63 (17.5)	0.338
CMV mismatch (D+/R-), N (%)	6 (15.8)	6 (24.0)	20 (21.5)	72 (20.3)	0.388

Table 2. Multipredictor model for cardiac mortality or retransplant as the outcome. AMR, antibody mediated rejection; CI, confidence interval; DCD, donation after cardiac death; HR, hazard ratio; pMCS, percutaneous mechanical circulatory support.

Variables	HR	95% CI	p-value
Medical nonadherence	3.45	[1.27-9.36]	p = 0.015
Recipient age (per 1-y increment)	0.97	[0.94-0.99]	p = 0.019
pMCS post-HTx	2.85	[0.89-9.10]	p = 0.077
Number of AMR episodes	1.62	[0.94-2.78]	p = 0.080
DCD	4.49	[0.81-24.84]	p = 0.085

Table 3. Multipredictor model for cardiac allograft dysfunction as the outcome. CI, confidence interval; DSA, donor-specific antibodies; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; HTx, heart transplantation; PHM, predicted heart mass; pMCS, percutaneous mechanical circulatory support.

Variables	HR	95% CI	p-value
Medical nonadherence	2.14	[1.27-3.60]	p = 0.005
C4d/DSA status	-	-	p = 0.007
PHM difference	1.02	[1.00-1.03]	p = 0.007
HTx indication	-	-	p = 0.020
ECMO pre-HTx	4.46	[1.17-16.97]	p = 0.028
ECMO post-HTx	2.43	[1.03-5.75]	p = 0.044
pMCS pre-HTx	0.55	[0.26-1.18]	p = 0.127

Supplemental Figure S1. Kaplan-Meier Curves for Freedom from C4d positivity in C4d+/DSA+ and C4d+/DSA- patients. Median time (diamond) to C4d positivity is 33.6 weeks from heart transplantation (IQR, 3.4-163.0 weeks) in C4d+/DSA+ patients. Median time (triangle) to C4d positivity is 3.6 weeks from heart transplantation (IQR, 1.6-9.4 weeks) in C4d+/DSA- patients. The C4d+/DSA+ group showed a significantly increased median time to C4d positivity compared to the C4d+/DSA- group (logrank p = 0.002).

Number at risk							
C4d+/DSA+	40	17	13	11	6	5	2
C4d+/DSA-	25	2	2	2	1	0	0

Supplementary Table S1. Patient outcomes compared across groups. ACR, acute cellular rejection; DSA, donor-specific antibody.

	C4d+/DSA+ (n = 40)	C4d+/DSA- (n = 25)	C4d-/DSA+ (n = 94)	C4d-/DSA- (n = 360)
All-cause mortality or cardiac retransplant (%)	11 (27.5)	3 (12.0)	6 (6.4)	38 (10.6)
Cardiovascular related death (%)	6 (15.0)	1 (4.0)	3 (3.2)	6 (1.7)
Infectious related mortality (%)	1 (2.5)	0	2 (2.1)	19 (5.3)
Cardiac allograft dysfunction (%)	20 (50.0)	3 (12.0)	15 (16.0)	43 (11.9)
Cardiac allograft vasculopathy (%)	8 (24.2)	2 (9.5)	6 (8.0)	14 (6.1)
Future ACR (%)	9 (24.3)	4 (16.0)	12 (12.8)	40 (11.2)

Supplementary Table S2. Multipredictor model for all cause death or cardiac retransplant as the outcome. BMI, body mass index; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; HTx, heart transplantation, PHM, predicted heart mass.

Variables	HR	95% CI	p-value
ECMO post-HTx	5.28	[2.16-12.90]	p < 0.001
Sex mismatch	-	-	p = 0.008
Recipient race/ethnicity	-	-	p = 0.012
Medical nonadherence	1.92	[1.06-3.46]	p = 0.030
Recipient BMI	0.93	[0.87-1.00]	p = 0.036
PHM difference	1.02	[1.00-1.04]	p = 0.046

Supplementary Table S3. Single predictor cox proportional hazards model for cardiac mortality or retransplant as the outcome. AMR, antibody mediated rejection; BMI, body mass index; CMV, cytomegalovirus; cPRA, calculated panel reactive antibodies; DSA, donor-specific antibodies; ECMO, extracorporeal membrane oxygenation; HTx, heart transplantation; MCS, mechanical circulatory support; PHM, predicted heart mass; pMCS, percutaneous mechanical circulatory support. *, allosensitized patients defined as having a UNOS cPRA >= 10%.

Variables	Total # of patients	Total # of events	Hazard ratio	95% confidence interval	p-value
Recipient characteristics					
Age (per 1-y increment)	519	20	0.96	[0.94-0.99]	0.004
Female sex	519	20	1.76	[0.67-4.61]	0.248
Race and ethnicity	519	20	-	-	0.219
Recipient BMI (per kg/m^2)	519	20	0.98	[0.90-1.08]	0.700
Multi-organ transplant	519	20	1.87	[0.62-5.65]	0.269
HTx indication	519	20	-	-	0.580
Allosensitization pre-HTx*	449	15	1.27	[0.40-3.99]	0.685
Blood type	512	20	-	-	0.553
Durable MCS at time of HTx	519	20	1.32	[0.55-3.18]	0.537
Medical nonadherence	519	20	4.52	[1.87-10.94]	0.001
Donor characteristics					
Age (per 1-y increment)	507	18	1.02	[0.98-1.06]	0.387
Donor BMI (per kg/m^2)	501	18	1.01	[0.94-1.09]	0.809
Transplant characteristics					
Induction therapy	505	18	1.12	[0.43-2.92]	0.816
Cold ischemic time	505	18	1.00	[0.99-1.01]	0.457
PHM difference	501	18	1.01	[0.99-1.03]	0.486

Donation after cardiac death	519	20	3.43	[0.63-18.63]	0.153
ECMO pre-HTx	515	19	3.99	[0.53-30.23]	0.180
ECMO post-HTx	515	19	4.48	[1.02-19.63]	0.047
pMCS pre-HTx	515	19	0.29	[0.04-2.19]	0.230
pMCS post-HTx	515	19	2.26	[0.74-6.91]	0.153
History of C4d positivity	519	20	3.96	[1.63-9.60]	0.002
Number of AMR episodes	518	19	2.07	[1.33-3.23]	0.001
History of DSA positivity	519	20	2.86	[1.18-6.91]	0.020
Class 1 Antibodies	519	20	3.86	[1.54-9.70]	0.004
Class 2 Antibodies	519	20	3.72	[1.54-8.98]	0.004
CMV mismatch	511	19	-	-	0.471
Sex mismatch	506	18	-	-	0.648
C4d/DSA Group	519	20	-	-	0.011

Supplementary Table S4. Multipredictor analysis for donor-specific antibody (DSA) positivity as the outcome. CI, confidence interval; HR, hazard ratio; cPRA, calculated panel of reactive antibodies; MCS, mechanical circulatory support; UNOS, United Network for Organ Sharing. *, allosensitized patients defined as having a UNOS cPRA >= 10%.

Variables	HR	95% CI	p-value
Recipient Age (per 1-y increment)	0.98	[0.96-0.99]	p < 0.001
Medical nonadherence	2.03	[1.33-3.08]	p = 0.001
Allosensitization pre-HTx*	1.55	[1.02-2.36]	p = 0.039
Durable MCS	0.71	[0.48-1.05]	p = 0.083

Supplementary Table S5. Multipredictor model for C4d positivity as the outcome. BMI, body mass index; CI, confidence interval; HR, hazard ratio.

Variables	HR	95% CI	p-value
Class 1 antibodies	3.04	[1.73-5.35]	p < 0.001
Class 2 antibodies	2.97	[1.71-5.16]	p < 0.001
Medical nonadherence	1.89	[1.11-3.21]	p = 0.019
Female recipient sex	1.77	[1.03-3.05]	p = 0.038
Recipient BMI	0.96	[0.92-1.01]	p = 0.126

Supplementary Table S6. Single predictor cox proportional hazards model for cardiac allograft dysfunction as the outcome. AMR, antibody mediated rejection; BMI, body mass index; CMV, cytomegalovirus; cPRA, calculated panel reactive antibodies; DSA, donor-specific antibodies; ECMO, extracorporeal membrane oxygenation; HTx, heart transplantation; MCS, mechanical circulatory support; PHM, predicted heart mass; pMCS, percutaneous mechanical circulatory support. *, allosensitized patients defined as having a UNOS cPRA >= 10%.

Variables	Total # of patients	Total # of events	Hazard ratio	95% confidence interval	p-value
Recipient characteristics					
Age (per 1-y increment)	519	78	1.01	[0.99-1.02]	0.568
Female sex	519	78	0.84	[0.49-1.45]	0.538
Race and ethnicity	519	78	-	-	0.593
Recipient BMI (per kg/m^2)	519	78	0.97	[0.92-1.02]	0.197
Multiorgan transplant	519	78	1.16	[0.63-2.15]	0.631
HTx indication	519	78	-	-	0.026
Allosensitization pre-HTx*	449	66	0.87	[0.47-1.64]	0.671
Blood type	512	77	-	-	0.664
Durable MCS at time of HTx	519	78	1.36	[0.87-2.13]	0.180
Medical nonadherence	519	78	2.49	[1.56-3.97]	<0.001
Donor characteristics					
Age (per 1-y increment)	507	76	0.99	[0.97-1.01]	0.256
Donor BMI (per kg/m^2)	501	73	0.97	[0.93-1.01]	0.140
Transplant characteristics					
Induction therapy	505	75	0.79	[0.50-1.26]	0.319
Cold ischemic time	505	76	1.00	[0.99-1.00]	0.375
PHM difference	501	73	1.01	[1.00-1.02]	0.011

Donation after cardiac death	519	78	1.41	[0.71-2.81]	0.326
ECMO pre-HTx	515	77	2.64	[0.83-8.41]	0.100
ECMO post-HTx	515	77	2.76	[1.19-6.37]	0.018
pMCS pre-HTx	515	77	0.57	[0.28-1.15]	0.116
pMCS post-HTx	515	77	1.43	[0.79-2.61]	0.240
History of C4d positivity	519	78	2.45	[1.50-3.98]	<0.001
Number of AMR episodes	518	77	1.51	[1.12-2.03]	0.007
History of DSA positivity	519	78	2.07	[1.32-3.23]	0.001
Class 1 Antibodies	519	78	3.13	[1.90-5.17]	<0.001
Class 2 Antibodies	519	78	2.48	[1.58-3.89]	<0.001
CMV mismatch	511	78	-	-	0.365
Sex mismatch	506	76	-	-	0.312
C4d/DSA Group	519	76	-	-	<0.001

Supplementary Table S7. Pairwise comparisons of C4d/DSA groups for cardiac allograft vasculopathy as the outcome. Pairwise comparisons were adjusted for the identified confounders of donor age, cold ischemic time, and predicted heart mass difference by the forward model selection procedure. CI, confidence interval; DSA, donor-specific antibodies; HR, hazard ratio. [#], reference is C4d-/DSA- group.

Variables	HR	95% CI	p-value
C4d+/DSA+[#]	3.52	[1.21-10.24]	p_c = 0.063
C4d+/DSA-[#]	1.63	[0.36-7.34]	p_c = 0.527
C4d-/DSA+[#]	1.98	[0.72-5.43]	p_c = 0.370

REFERENCES

1.   Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, Gay WA Jr, Jones KW, O'Connell JB. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. *J Heart Transplant* [Internet]. 1989;8:430–443. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2693662

2.   Ensley RD, Hammond EH, Renlund DG, Yowell RL, Bristow MR, DeWitt CW, Menlove RL, Ratkovec RM, O'Connell JB. Clinical manifestations of vascular rejection in cardiac transplantation. *Transplant Proc* [Internet]. 1991;23:1130–1132. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1989167

3.   Cherry R, Nielsen H, Reed E, Reemtsma K, Suciu-Foca N, Marboe CC. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. *J Heart Lung Transplant* [Internet]. 1992;11:24–9; discussion 30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1540608

4.   Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, Goddard M, Hammond EH, Leone O, Marboe C, Miller D, Neil D, Rassl D, Revelo MP, Rice A, Rene Rodriguez E, Stewart S, Tan CD, Winters GL, West L, Mehra MR, Angelini A. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* [Internet]. 2013;32:1147–1162. Available from: http://dx.doi.org/10.1016/j.healun.2013.08.011

5.   Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, Kobashigawa JA, Lindenfeld J, Masri SC, Miller D, O'Connell J, Rodriguez ER, Rosengard B, Self S, White-Williams C, Zeevi A, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation, American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Radiology and Intervention, American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Surgery and Anesthesia. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. *Circulation* [Internet]. 2015;131:1608–1639. Available from: http://dx.doi.org/10.1161/CIR.0000000000000093

6.   Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A, Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* [Internet]. 2011;30:252–269. Available from: http://dx.doi.org/10.1016/j.healun.2010.11.003

7.   Husain AN, Mirza KM, Fedson SE. Routine C4d immunohistochemistry in cardiac

allografts: Long-term outcomes. *J Heart Lung Transplant* [Internet]. 2017;36:1329–1335. Available from: http://dx.doi.org/10.1016/j.healun.2017.09.004

8. Clerkin KJ, Farr MA, Restaino SW, Zorn E, Latif F, Vasilescu ER, Marboe CC, Colombo PC, Mancini DM. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. *J Heart Lung Transplant* [Internet]. 2017;36:540–545. Available from: http://dx.doi.org/10.1016/j.healun.2016.10.016

9. Luk A, Alba AC, Butany J, Tinckam K, Delgado D, Ross HJ. C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients. *Transpl Int* [Internet]. 2015;28:857–863. Available from: http://dx.doi.org/10.1111/tri.12560

10. Hammond MEH, Revelo MP, Miller DV, Snow GL, Budge D, Stehlik J, Molina KM, Selzman CH, Drakos SG, Rami A A, Nativi-Nicolau JN, Reid BB, Kfoury AG. ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis. *J Heart Lung Transplant* [Internet]. 2016;35:320–325. Available from: http://dx.doi.org/10.1016/j.healun.2015.10.035

11. Coutance G, Kransdorf E, Aubert O, Bonnet G, Yoo D, Rouvier P, Duong Van Huyen J-P, Bruneval P, Taupin J-L, Leprince P, Varnous S, Kobashigawa J, Jouven X, Patel J, Loupy A. Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation. *Circ Heart Fail* [Internet]. 2022;15:e009923. Available from: http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.009923

12. Fedrigo M, Gambino A, Tona F, Torregrossa G, Poli F, Benazzi E, Frigo A, Feltrin G, Toscano G, Caforio AP, Iliceto S, Valente M, Thiene G, Gerosa G, Angelini A. Can C4d Immunostaining on Endomyocardial Biopsies Be Considered a Prognostic Biomarker in Heart Transplant Recipients? [Internet]. Transplantation. 2010;90:791–798. Available from: http://dx.doi.org/10.1097/tp.0b013e3181efd059

13. Loupy A, Duong Van Huyen JP, Hidalgo L, Reeve J, Racapé M, Aubert O, Venner JM, Falmuski K, Bories MC, Beuscart T, Guillemain R, François A, Pattier S, Toquet C, Gay A, Rouvier P, Varnous S, Leprince P, Empana JP, Lefaucheur C, Bruneval P, Jouven X, Halloran PF. Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection. *Circulation* [Internet]. 2017;135:917–935. Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022907

14. Mantell BS, Cordero H, See SB, Clerkin KJ, Vasilescu R, Marboe CC, Naka Y, Restaino S, Colombo PC, Addonizio LJ, Farr MA, Zorn E. Transcriptomic heterogeneity of antibody mediated rejection after heart transplant with or without donor specific antibodies. *J Heart Lung Transplant* [Internet]. 2021;40:1472–1480. Available from: http://dx.doi.org/10.1016/j.healun.2021.06.012

15. Tambur AR, Leventhal J, Kaufman DB, Friedewald J, Miller J, Abecassis MM. Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: the Northwestern University experience. *Transplantation* [Internet]. 2008;86:1052–1059. Available from: http://dx.doi.org/10.1097/TP.0b013e3181874b06

16. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. MONITORING OF

SOLUBLE HLA ALLOANTIGENS AND ANTI-HLA ANTIBODIES IDENTIFIES HEART ALLOGRAFT RECIPIENTS AT RISK OF TRANSPLANT-ASSOCIATED CORONARY ARTERY DISEASE1. *Transplantation* [Internet]. 1996 [cited 2023 Nov 25];61:566. Available from: https://journals.lww.com/transplantjournal/Fulltext/1996/02270/MONITORING_OF_SOLUBLE_HLA_ALLOANTIGENS_AND.9.aspx

17. Zhang Q, Hickey M, Drogalis-Kim D, Zheng Y, Gjertson D, Cadeiras M, Khuu T, Baas AS, Depasquale EC, Halnon NJ, Perens G, Alejos J, Cruz D, Ali N, Shemin R, Kwon M, Fishbein MC, Ardehali A, Deng M, Reed EF. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients. *Transplantation* [Internet]. 2018;102:e431–e438. Available from: http://dx.doi.org/10.1097/TP.0000000000002333

18. Moayedi Y, Fan C-PS, Tinckam KJ, Ross HJ, McCaughan JA. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA? *Clin Transplant* [Internet]. 2018;32:e13416. Available from: http://dx.doi.org/10.1111/ctr.13416

19. Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, Terasaki PI, Rose ML. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. *Am J Transplant* [Internet]. 2011;11:312–319. Available from: http://dx.doi.org/10.1111/j.1600-6143.2010.03383.x

20. Frank R, Molina MR, Wald JW, Goldberg LR, Kamoun M, Lal P. Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: a single-center, retrospective study. *J Heart Lung Transplant* [Internet]. 2013;32:410–417. Available from: http://dx.doi.org/10.1016/j.healun.2012.12.005

21. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant* [Internet]. 2005;24:1710–1720. Available from: http://dx.doi.org/10.1016/j.healun.2005.03.019

22. Zavyalova D, Abraha J, Rao P, Morris GP. Incidence and impact of allele-specific anti-HLA antibodies and high-resolution HLA genotyping on assessing immunologic compatibility. *Hum Immunol* [Internet]. 2021;82:147–154. Available from: http://dx.doi.org/10.1016/j.humimm.2021.01.002

23. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen J, Parameshwar J, Starling RC, Uber PA. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. *J Heart Lung Transplant* [Internet]. 2010;29:717–727. Available from: http://dx.doi.org/10.1016/j.healun.2010.05.017

24. Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M, Mancini D, Patel J, Razi R, Reichenspurner H, Russell S, Segovia J, Smedira N, Stehlik J, Wagner F, Consensus Conference participants. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. *J Heart Lung Transplant* [Internet]. 2014;33:327–

340. Available from: http://dx.doi.org/10.1016/j.healun.2014.02.027

25. Therneau, Grambsch. Modeling Survival Data: Extending the Cox Model 2000 New York. *NY Springer Crossref*.

26. Gray B. cmprsk: Subdistribution analysis of competing risks. *R package version*. 2014;

27. Nakazawa M. fmsb: Functions for Medical Statistics Book with some Demographic Data [Internet]. 2023. Available from: https://CRAN.R-project.org/package=fmsb

28. Wickham H. ggplot2: elegant graphics for data analysis Springer-Verlag New York; 2009. 2016;

29. Rodgers N, Gerding B, Cusi V, Vaida F, Tada Y, Morris GP, Adler ED, Stehlik J, Kim PJ. Comparison of two donor-derived cell-free DNA tests and a blood gene-expression profile test in heart transplantation. *Clin Transplant* [Internet]. 2023;37:e14984. Available from: http://dx.doi.org/10.1111/ctr.14984

30. Tan CD, Sokos GG, Pidwell DJ, Smedira NG, Gonzalez-Stawinski GV, Taylor DO, Starling RC, Rodriguez ER. Correlation of Donor-Specific Antibodies, Complement and Its Regulators with Graft Dysfunction in Cardiac Antibody-Mediated Rejection [Internet]. American Journal of Transplantation. 2009;9:2075–2084. Available from: http://dx.doi.org/10.1111/j.1600-6143.2009.02748.x

31. Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, Farrero M, García-Guereta L, Jamero G, Khush K, Lavee J, Pouch S, Patel J, Michaud CJ, Shullo MA, Schubert S, Angelini A, Carlos L, Mirabet S, Patel J, Pham M, Urschel S, Kim K-H, Miyamoto S, Chih S, Daly K, Grossi P, Jennings DL, Kim I-C, Lim HS, Miller T, Potena L, Velleca A, Eisen H, Bellumkonda L, Danziger-Isakov L, Dobbels F, Harkess M, Kim D, Lyster H, Peled Y, Reinhardt Z. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* [Internet]. 2023;42:e1–e141. Available from: http://dx.doi.org/10.1016/j.healun.2022.10.015

32. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, Gay WA Jr, Jones KW, O'Connell JB. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. *J Heart Transplant* [Internet]. 1989;8:430–443. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2693662

33. Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. *J Heart Lung Transplant* [Internet]. 1995;14:151–162. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7727464

34. Kfoury AG, Hammond MEH, Snow GL, Stehlik J, Reid BB, Long JW, Gilbert EM, Bader FM, Bull DA, Renlund DG. Early screening for antibody-mediated rejection in heart transplant recipients. *J Heart Lung Transplant* [Internet]. 2007;26:1264–1269. Available from: http://dx.doi.org/10.1016/j.healun.2007.09.011

35. Almuti K, Haythe J, Dwyer E, Itescu S, Burke E, Green P, Marboe C, Mancini D. The changing pattern of humoral rejection in cardiac transplant recipients. *Transplantation*

[Internet]. 2007;84:498–503. Available from: http://dx.doi.org/10.1097/01.tp.0000278094.41131.9f

36. Fedrigo M, Gambino A, Benazzi E, Poli F, Frigo AC, Tona F, Caforio ALP, Castellani C, Toscano G, Feltrin G, Gerosa G, Thiene G, Angelini A. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* [Internet]. 2011;30:1381–1388. Available from: http://dx.doi.org/10.1016/j.healun.2011.07.012

37. Loupy A, Toquet C, Rouvier P, Beuscart T, Bories MC, Varnous S, Guillemain R, Pattier S, Suberbielle C, Leprince P, Lefaucheur C, Jouven X, Bruneval P, Duong Van Huyen JP. Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection. *Am J Transplant* [Internet]. 2016;16:111–120. Available from: http://dx.doi.org/10.1111/ajt.13529

38. Uraizee I, Varma VK, Sreedhar H, Gambacorta F, Nazeer SS, Husain A, Walsh MJ. Label-free Identification of Antibody-mediated Rejection in Cardiac Allograft Biopsies Using Infrared Spectroscopic Imaging. *Transplantation* [Internet]. 2019;103:698–704. Available from: http://dx.doi.org/10.1097/TP.0000000000002465

39. Crespo-Leiro MG, Veiga-Barreiro A, Doménech N, Paniagua MJ, Piñón P, González-Cuesta M, Vázquez-Martul E, Ramirez C, Cuenca JJ, Castro-Beiras A. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. *Am J Transplant* [Internet]. 2005;5:2560–2564. Available from: http://dx.doi.org/10.1111/j.1600-6143.2005.01039.x

40. Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, Baldwin WM. Antibody-Mediated Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d as Markers. *Am J Transplant* [Internet]. 2005;5:2778–2785. Available from: https://www.sciencedirect.com/science/article/pii/S1600613522143364

41. Baldwin WM 3rd, Samaniego-Picota M, Kasper EK, Clark AM, Czader M, Rohde C, Zachary AA, Sanfilippo F, Hruban RH. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. *Transplantation* [Internet]. 1999;68:894–900. Available from: http://dx.doi.org/10.1097/00007890-199909270-00024

42. Bayliss J, Bailey M, Leet A, Thomson N, McLean C. Late Onset Antibody-mediated Rejection and Endothelial Localisation of Vascular Endothelial Growth Factor are Associated with Development of Cardiac Allograft Vasculopathy. *Heart Lung Circ* [Internet]. 2008;17:S3. Available from: https://www.heartlungcirc.org/article/S1443-9506(08)00192-3/abstract

43. de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders MEJ, Schaapherder AF, van Kooten C. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. *Transplantation* [Internet]. 2013;95:816–820. Available from: http://dx.doi.org/10.1097/TP.0b013e31827e31c9

44. Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, Kiyosaki KK,

Ardehali A. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. *J Heart Lung Transplant* [Internet]. 2009;28:417–422. Available from: http://dx.doi.org/10.1016/j.healun.2009.01.015

45. Moseley EL, Atkinson C, Sharples LD, Wallwork J, Goddard MJ. Deposition of C4d and C3d in cardiac transplants: a factor in the development of coronary artery vasculopathy. *J Heart Lung Transplant* [Internet]. 2010;29:417–423. Available from: http://dx.doi.org/10.1016/j.healun.2009.12.018

46. Bayliss J, Bailey M, Leet A, Stein AN, Thomson NM, McLean CA. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy. *Transplantation* [Internet]. 2008;86:991–997. Available from: http://dx.doi.org/10.1097/TP.0b013e318186d734

47. Poelzl G, Ullrich R, Huber A, Ulmer H, Antretter H, Hoefer D, Mairinger T, Laufer G, Pachinger O, Schwarzacher S. Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy. *Transpl Int* [Internet]. 2005;18:313–317. Available from: http://dx.doi.org/10.1111/j.1432-2277.2004.00037.x

48. Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, Reed EF, Fishbein MC. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. *J Heart Lung Transplant* [Internet]. 2003;22:58–69. Available from: http://dx.doi.org/10.1016/s1053-2498(02)00472-2

49. Coutance G, Ouldamar S, Rouvier P, Saheb S, Suberbielle C, Bréchot N, Hariri S, Lebreton G, Leprince P, Varnous S. Late antibody-mediated rejection after heart transplantation: Mortality, graft function, and fulminant cardiac allograft vasculopathy. *J Heart Lung Transplant* [Internet]. 2015;34:1050–1057. Available from: http://dx.doi.org/10.1016/j.healun.2015.03.002

50. Tambur AR, Pamboukian SV, Costanzo M-R, Herrera ND, Dunlap S, Montpetit M, Heroux A. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. *Transplantation* [Internet]. 2005;80:1019–1025. Available from: http://dx.doi.org/10.1097/01.tp.0000180564.14050.49

51. Zhang X, Kransdorf E, Levine R, Patel JK, Kobashigawa JA. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. *Hum Immunol* [Internet]. 2020;81:330–336. Available from: http://dx.doi.org/10.1016/j.humimm.2020.04.003

52. Jaiswal A, Bell J, DeFilippis EM, Kransdorf EP, Patel J, Kobashigawa JA, Kittleson MM, Baran DA. Assessment and management of allosensitization following heart transplant in adults. *J Heart Lung Transplant* [Internet]. 2023;42:423–432. Available from: http://dx.doi.org/10.1016/j.healun.2022.12.011

53. Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS, CTOT-05 consortium. Multicenter analysis of immune biomarkers and heart transplant outcomes: Results of the Clinical Trials in Organ Transplantation-05 study. *Am J Transplant* [Internet]. 2016;16:121–136. Available from:

https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.13422

54. Cole RT, Gandhi J, Bray RA, Gebel HM, Yin M, Shekiladze N, Young A, Grant A, Mahoney I, Laskar SR, Gupta D, Bhatt K, Book W, Smith A, Nguyen D, Vega JD, Morris AA. Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation. *J Heart Lung Transplant* [Internet]. 2018;37:503–512. Available from: http://dx.doi.org/10.1016/j.healun.2017.11.003

55. Akhtar W, Peterzan MA, Banya W, Olwell B, Aghouee FV, Brookes P, Dunning J, Dar O. Donor specific antibodies association with survival and adverse events after heart transplantation: A single center retrospective study between 2006 and 2021. *Clin Transplant* [Internet]. 2023;37:e14914. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.14914

56. Huang Y, Dinh A, Heron S, Gasiewski A, Kneib C, Mehler H, Mignogno MT, Morlen R, Slavich L, Kentzel E, Frackelton EC, Duke JL, Ferriola D, Mosbruger T, Timofeeva OA, Geier SS, Monos D. Assessing the utilization of high-resolution 2-field HLA typing in solid organ transplantation. *Am J Transplant* [Internet]. 2019;19:1955–1963. Available from: https://linkinghub.elsevier.com/retrieve/pii/S160061352209150X

57. Yopes M, Fanek T, Fuselier B, Gaine M, Jackson R, Mabasa A, Kim A, Jennings DL, Clerkin K, Yuzefpolskaya M, Habal M, Latif F, Restaino S, Lee SH, Farr M, Colombo P, Sayer G, Uriel N. Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donor-specific antibody levels. *Clin Transplant* [Internet]. 2022;36:e14524. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.14524

58. Law YM, Nandi D, Molina K, Gambetta K, Daly KP, Das B. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. *Cardiol Young* [Internet]. 2020;30:107–113. Available from: http://dx.doi.org/10.1017/S1047951119003056

59. Tang Z, Kobashigawa J, Rafiei M, Stern LK, Hamilton M. The natural history of biopsy-negative rejection after heart transplantation. *J Transplant* [Internet]. 2013;2013:236720. Available from: http://dx.doi.org/10.1155/2013/236720

60. Lefaucheur C, Louis K, Morris AB, Taupin J-L, Nickerson P, Tambur AR, Gebel HM, Reed EF, Kobashigawa JA, Chandraker A, Others. Clinical recommendations for posttransplant assessment of anti--HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. *Am J Transplant* [Internet]. 2023;23:115–132. Available from: https://www.sciencedirect.com/science/article/pii/S1600613522272529

61. Halloran PF, Madill-Thomsen K, Aliabadi-Zuckermann AZ, Cadeiras M, Crespo-Leiro MG, Depasquale EC, Deng M, Gökler J, Kim DH, Kobashigawa J, Macdonald P, Potena L, Shah K, Stehlik J, Zuckermann A. Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes. *J Heart Lung Transplant* [Internet]. 2022;41:334–344. Available from: http://dx.doi.org/10.1016/j.healun.2021.08.004

62. Kfoury AG, Stehlik J, Renlund DG, Snow G, Seaman JT, Gilbert EM, Stringham JS, Long JW, Hammond MEH. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection

patterns. *J Heart Lung Transplant* [Internet]. 2006;25:1277–1282. Available from: http://dx.doi.org/10.1016/j.healun.2006.08.009

63. Glass C, Butt YM, Gokaslan ST, Torrealba JR. CD68/CD31 immunohistochemistry double stain demonstrates increased accuracy in diagnosing pathologic antibody-mediated rejection in cardiac transplant patients. *Am J Transplant* [Internet]. 2019;19:3149–3154. Available from: https://www.sciencedirect.com/science/article/pii/S1600613522093066